ForPatients
by Roche

Healthy Volunteers

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03236844 WP40052

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administration.

Hoffmann-La Roche Sponsor	**Phase 1** Phase

NCT03236844 WP40052
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 80 Years	Accepts Healthy Volunteers

© 2022 F. Hoffmann-La Roche Ltd